{"entity":{"id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","aka":[],"tldr":"A phase 1/2 trial of Cyclophosphamide and Fludarabine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by ARCE Therapeutics, Inc., now recruiting.","summary":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS is a phase 1/2 interventional study registered as NCT06680752 by ARCE Therapeutics, Inc., with 49 participants planned, started 2025-05-20 and due to reach its primary completion in 2028-10. Interventions recorded: ARD103, Cyclophosphamide and Fludarabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06680752","url":"https://clinicaltrials.gov/study/NCT06680752"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","fludarabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06680752","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"ARCE Therapeutics, Inc.","enrolled":49,"outcomes":[]},"route":"/trials/nct06680752/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"ard103","kind":"drug","name":"ARD103","route":"/drugs/ard103/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}